Mayne Pharma Group Limited (MAYNF)
USD 4.25
(-2.3%)
USD 4.25
(-2.3%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -78.42 Million AUD | -31.43% |
| 2023 | -54.2 Million AUD | -117.1% |
| 2022 | 316.99 Million AUD | 27.39% |
| 2021 | 248.83 Million AUD | -4.39% |
| 2020 | 260.26 Million AUD | -7.17% |
| 2019 | 280.37 Million AUD | -2.27% |
| 2018 | 286.87 Million AUD | 3.48% |
| 2017 | 277.21 Million AUD | 818.28% |
| 2016 | 30.18 Million AUD | 1081.57% |
| 2015 | 2.55 Million AUD | -92.31% |
| 2014 | 33.21 Million AUD | 19.66% |
| 2013 | 27.76 Million AUD | 339.39% |
| 2012 | -11.59 Million AUD | -234.37% |
| 2011 | -3.46 Million AUD | 68.74% |
| 2010 | -11.09 Million AUD | -39.83% |
| 2009 | -7.93 Million AUD | 31.16% |
| 2008 | -11.52 Million AUD | 24.65% |
| 2007 | -15.29 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -78.42 Million AUD | -7.95% |
| 2024 Q4 | -78.42 Million AUD | 9.16% |
| 2024 Q2 | -72.65 Million AUD | 4.56% |
| 2024 FY | -73.56 Million AUD | -35.71% |
| 2024 Q1 | -76.12 Million AUD | -124.01% |
| 2023 Q2 | -94.3 Million AUD | 3.13% |
| 2023 FY | -54.2 Million AUD | -117.1% |
| 2023 Q1 | -97.35 Million AUD | -130.75% |
| 2023 Q4 | 316.99 Million AUD | 750.54% |
| 2023 Q3 | -48.72 Million AUD | 48.33% |
| 2022 Q2 | 272.53 Million AUD | 0.96% |
| 2022 Q4 | 316.58 Million AUD | 0.71% |
| 2022 FY | 316.99 Million AUD | 27.39% |
| 2022 Q3 | 314.36 Million AUD | 15.35% |
| 2022 Q1 | 269.95 Million AUD | 8.48% |
| 2021 Q1 | 220.08 Million AUD | -15.44% |
| 2021 FY | 248.83 Million AUD | -4.39% |
| 2021 Q2 | 220.57 Million AUD | 0.22% |
| 2021 Q4 | 248.83 Million AUD | 0.73% |
| 2021 Q3 | 247.03 Million AUD | 12.0% |
| 2020 Q4 | 260.26 Million AUD | 0.05% |
| 2020 FY | 260.26 Million AUD | -7.17% |
| 2020 Q2 | 290.16 Million AUD | 0.99% |
| 2020 Q3 | 260.14 Million AUD | -10.35% |
| 2020 Q1 | 287.31 Million AUD | 2.47% |
| 2019 Q4 | 280.37 Million AUD | -0.15% |
| 2019 FY | 280.37 Million AUD | -2.27% |
| 2019 Q3 | 280.79 Million AUD | -5.9% |
| 2019 Q1 | 298.4 Million AUD | 4.02% |
| 2019 Q2 | 298.4 Million AUD | 0.0% |
| 2018 Q4 | 286.87 Million AUD | 0.02% |
| 2018 Q2 | 303.13 Million AUD | 0.0% |
| 2018 FY | 286.87 Million AUD | 3.48% |
| 2018 Q1 | 303.13 Million AUD | 9.35% |
| 2018 Q3 | 286.82 Million AUD | -5.38% |
| 2017 Q3 | 277.1 Million AUD | 19.31% |
| 2017 Q2 | 232.25 Million AUD | 0.0% |
| 2017 Q4 | 277.21 Million AUD | 0.04% |
| 2017 Q1 | 232.25 Million AUD | 669.34% |
| 2017 FY | 277.21 Million AUD | 818.28% |
| 2016 FY | 30.18 Million AUD | 1081.57% |
| 2016 Q1 | 15.06 Million AUD | 489.47% |
| 2016 Q4 | 30.18 Million AUD | 4.64% |
| 2016 Q3 | 28.85 Million AUD | 91.55% |
| 2016 Q2 | 15.06 Million AUD | 0.0% |
| 2015 Q3 | 2.55 Million AUD | -93.57% |
| 2015 Q2 | 39.73 Million AUD | 0.0% |
| 2015 FY | 2.55 Million AUD | -92.31% |
| 2015 Q4 | 2.55 Million AUD | 0.0% |
| 2015 Q1 | 39.73 Million AUD | 19.61% |
| 2014 FY | 33.21 Million AUD | 19.66% |
| 2014 Q2 | 35.72 Million AUD | 0.0% |
| 2014 Q3 | 33.21 Million AUD | -7.03% |
| 2014 Q4 | 33.21 Million AUD | 0.0% |
| 2014 Q1 | 35.72 Million AUD | 28.7% |
| 2013 FY | 27.76 Million AUD | 339.39% |
| 2013 Q3 | 27.76 Million AUD | 0.0% |
| 2013 Q4 | 27.76 Million AUD | 0.0% |
| 2012 Q4 | -11.59 Million AUD | 0.0% |
| 2012 FY | -11.59 Million AUD | -234.37% |
| 2011 FY | -3.46 Million AUD | 68.74% |
| 2011 Q4 | -3.46 Million AUD | 0.0% |
| 2010 Q4 | -11.09 Million AUD | 0.0% |
| 2010 FY | -11.09 Million AUD | -39.83% |
| 2009 Q4 | -7.93 Million AUD | 0.0% |
| 2009 FY | -7.93 Million AUD | 31.16% |
| 2008 FY | -11.52 Million AUD | 24.65% |
| 2008 Q4 | -11.52 Million AUD | 0.0% |
| 2007 FY | -15.29 Million AUD | 0.0% |
| 2007 Q4 | -15.29 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 100.345% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 100.261% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 95.08% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 594.683% |
| Novartis AG | 12.95 Billion USD | 100.605% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | 53.785% |